When patients with de novo lesions in small-vessel disease are treated with the present-generation drug-eluting stents (DES), there is a higher risk for major adverse cardiac events (MACE) compared with patients treated with the new-generation paclitaxel drug-coated balloon (DCB), a long-term follow-up study shows.